Halozyme Therapeutics stock price target raised to $91 by Citizens JMP

Published 06/08/2025, 09:56
Halozyme Therapeutics stock price target raised to $91 by Citizens JMP

Investing.com - Citizens JMP raised its price target on Halozyme Therapeutics (NASDAQ:HALO) to $91.00 from $78.00 on Wednesday, maintaining a Market Outperform rating on the stock. According to InvestingPro data, the stock currently trades at an attractive PEG ratio of 0.28, suggesting it may be undervalued relative to its growth potential.

The price target increase follows Halozyme’s second-quarter 2025 financial results, which exceeded both Citizens JMP’s and consensus estimates. The company also raised its top-line and bottom-line guidance for 2025. The company’s strong financial health is reflected in its impressive 25.65% revenue growth and robust current ratio of 8.39, as reported by InvestingPro.

Citizens JMP now projects that Halozyme’s royalty revenue will surpass $1 billion in 2026, noting that "royalty growth continues to outpace expectations." The firm has increased its estimates for both 2025 and 2026, with projected royalties and adjusted EBITDA now above the company’s 2026 guidance ranges.

The research firm also highlighted management’s "aggressive use of the share buy-back program," taking advantage of stock volatility during the second quarter of 2025.

Halozyme Therapeutics develops technologies that enhance drug delivery, with its ENHANZE technology being used by multiple pharmaceutical partners for subcutaneous administration of medications.

In other recent news, Halozyme Therapeutics reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved an earnings per share (EPS) of $1.54, which exceeded analyst expectations of $1.24 by 24.19%. However, the revenue figures were less favorable, with Halozyme generating $206 million, falling short of the anticipated $286.01 million by 27.97%. Additionally, Morgan Stanley (NYSE:MS) upgraded Halozyme’s stock from Equalweight to Overweight, setting a new price target of $75.00, up from $62.00. This upgrade was influenced by the passage of the One Big Beautiful Bill, specifically the ORPHAN Cures Act, which Morgan Stanley views as beneficial for Halozyme. The investment firm highlighted that certain drugs, such as Vyvgart, Darzalex IV, and the first indication for Opdivo (melanoma), might be excluded from price negotiations, which could positively impact the company. These developments mark significant recent changes for Halozyme.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.